Laboratorios Richmond SACIF (RICH) - Total Assets
Based on the latest financial reports, Laboratorios Richmond SACIF (RICH) holds total assets worth AR$354.98 Billion ARS (≈ $256.86 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RICH book value for net asset value and shareholders' equity analysis.
Laboratorios Richmond SACIF - Total Assets Trend (2006–2024)
This chart illustrates how Laboratorios Richmond SACIF's total assets have evolved over time, based on quarterly financial data.
Laboratorios Richmond SACIF - Asset Composition Analysis
Current Asset Composition (December 2024)
Laboratorios Richmond SACIF's total assets of AR$354.98 Billion consist of 26.4% current assets and 73.6% non-current assets.
| Asset Category | Amount (ARS) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AR$0.00 | 2.7% |
| Accounts Receivable | AR$28.17 Billion | 10.8% |
| Inventory | AR$25.39 Billion | 9.8% |
| Property, Plant & Equipment | AR$0.00 | 0.0% |
| Intangible Assets | AR$26.08 Billion | 10.0% |
| Goodwill | AR$4.16 Billion | 1.6% |
Asset Composition Trend (2006–2024)
This chart illustrates how Laboratorios Richmond SACIF's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Laboratorios Richmond SACIF market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Laboratorios Richmond SACIF's current assets represent 26.4% of total assets in 2024, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2024, down from 6.2% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 10.8% of total assets.
Laboratorios Richmond SACIF Competitors by Total Assets
Key competitors of Laboratorios Richmond SACIF based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Laboratorios Richmond SACIF - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.05 | 1.23 | 1.51 |
| Quick Ratio | 0.60 | 0.74 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AR$4.32 Billion | AR$10.88 Billion | AR$1.82 Billion |
Laboratorios Richmond SACIF - Advanced Valuation Insights
This section examines the relationship between Laboratorios Richmond SACIF's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -22.9% |
| Total Assets | AR$260.15 Billion |
| Market Capitalization | $76.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Laboratorios Richmond SACIF's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Laboratorios Richmond SACIF's assets decreased by 22.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Laboratorios Richmond SACIF (2006–2024)
The table below shows the annual total assets of Laboratorios Richmond SACIF from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AR$260.15 Billion ≈ $188.25 Million |
-22.88% |
| 2023-12-31 | AR$337.32 Billion ≈ $244.09 Million |
+728.40% |
| 2022-12-31 | AR$40.72 Billion ≈ $29.47 Million |
+58.49% |
| 2021-12-31 | AR$25.69 Billion ≈ $18.59 Million |
+215.90% |
| 2020-12-31 | AR$8.13 Billion ≈ $5.89 Million |
+58.40% |
| 2019-12-31 | AR$5.13 Billion ≈ $3.72 Million |
+89.81% |
| 2018-12-31 | AR$2.71 Billion ≈ $1.96 Million |
+74.23% |
| 2017-12-31 | AR$1.55 Billion ≈ $1.12 Million |
+80.30% |
| 2016-12-31 | AR$861.13 Million ≈ $623.12K |
+61.61% |
| 2015-12-31 | AR$532.83 Million ≈ $385.56K |
+38.16% |
| 2014-12-31 | AR$385.66 Million ≈ $279.06K |
+34.20% |
| 2013-12-31 | AR$287.37 Million ≈ $207.94K |
+6.06% |
| 2012-12-31 | AR$270.95 Million ≈ $196.06K |
+70.39% |
| 2011-12-31 | AR$159.03 Million ≈ $115.07K |
+17.12% |
| 2010-12-31 | AR$135.78 Million ≈ $98.25K |
+6.21% |
| 2009-12-31 | AR$127.84 Million ≈ $92.51K |
+27.03% |
| 2008-12-31 | AR$100.63 Million ≈ $72.82K |
+29.71% |
| 2007-12-31 | AR$77.58 Million ≈ $56.14K |
+37.67% |
| 2006-12-31 | AR$56.36 Million ≈ $40.78K |
-- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more